213: Thrombotic complications

Thrombotic complications of myeloma therapy.

Patients with multiple myeloma are at relatively high baseline risk of developing thromboembolic events (TEE), usually deep vein thromboses. There are numerous contributing factors, among them certain treatment regimens that include thalidomide or related compounds such as lenalidomide combined with glucocorticoids and/or cytotoxic chemotherapy. The risk of developing TEE appears to be particul...

Major complications in 213 laparoscopic nephrectomy cases: the Indianapolis experience.

PURPOSE We assessed the incidence of and analyzed factors that may help prevent major complications and open conversion during laparoscopic nephrectomy at our institutions. MATERIALS AND METHODS We retrospectively analyzed all laparoscopic nephrectomies performed between August 1, 1999 and July 31, 2001. Data were stratified for nephrectomy type, intraoperative and postoperative complications...

Hypercoagulability and thrombotic complications in hemolytic anemias.

Hemorrhagic and thrombotic complications in patients with myeloproliferative diseases.

OBJECTIVE To correlate the incidence of hemorrhage and thrombosis to bleeding time (BT) and platelet aggregation in 27 consecutive patients with myeloproliferative diseases (MPD). DESIGN Retrospective study. SETTING Public tertiary referral center. PATIENTS Eighteen patients with chronic myelogenous leukemia (CML), 5 with polycytemia vera (PV), 2 with essential thrombocytemia (ET) and 2 w...

Thrombotic complications in heart failure: an underappreciated challenge.

A dvances in pharmacologic and device therapy have greatly improved prognosis in patients with systolic heart failure. Despite this, congestive heart failure still bears a very grim prognosis, particularly in patients with more advanced stages of the disease, who are so frequently seen on hospital wards. Which pathogenic pathways may need to be addressed to improve prognosis in heart failure? T...